Lumiliximab, also known as ST-152, represents a novel monoclonal targeting the soluble protein for IL -13. This specific compound demonstrates notable potential in managing fibrotic conditions , https://andrewtlye249336.activoblog.com/51399473/lumiliximab-a-thorough-dive-into-the-st-152-monoclonal